三元生物面临美欧反倾销税影响，阿洛酮糖项目推进中

Core Viewpoint - Sanyuan Biotech is facing multiple dynamics including the final ruling of anti-dumping duties in the U.S., progress on the allulose project, and the promotion of new products [1] Group 1: Stock Recent Trends - The U.S. Department of Commerce has announced a final ruling on anti-dumping and countervailing investigations regarding Chinese erythritol products, with Sanyuan Biotech facing a comprehensive execution tax rate of 93.58% for exports to the U.S. This ruling will take effect upon publication in the Federal Register and may have a lasting impact on the company's U.S. market operations [2] - The European Union will impose a 156.7% anti-dumping tax on Chinese erythritol starting January 2025, lasting for five years. The company has responded by launching blended products, indicating that the impact of this event may persist [2] Group 2: Company Project Progress - The company's annual production project for 20,000 tons of allulose has completed the construction of the main engineering and equipment installation for the remaining 10,000 tons of capacity. The next steps will involve organizing environmental assessments and gradually advancing production. This project aims to enrich the product portfolio, but the production schedule and benefits are subject to approval processes and market demand [3] Group 3: Business Development Status - Sanyuan Biotech is continuously providing samples of Reb M to domestic and international potential customers and conducting application experiments. Some customers have already incorporated it into their reduced-sugar product formulations. Tagatose, as a key new functional sugar, is in a critical phase of market promotion and industrial application [4] Group 4: Company Status - The company will hold a board meeting on February 4, 2026, to review the proposal for convening the first extraordinary shareholders' meeting of 2026, with further arrangements to be announced [5]